Company intelligence / Profile preview

Calixa Therapeutics

San Diego, California, United Statescrunchbase.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Calixa Therapeutics developed novel antibiotics to address multi-drug resistant Gram-negative bacteria. Its lead compound, CXA‑201—a combination of the cephalosporin CXA‑101 and β-lactamase inhibitor tazobactam—was in Phase 2 trials for complicated urinary tract infections at the time of its acquisition by Cubist Pharmaceuticals. The company had global rights to develop and commercialize this asset outside select Asia-Pacific territories. No further independent clinical results were reported after the acquisition.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (novel cephalosporin antibiotics)
Industry: Biotech

Drug pipeline

1 asset

CXA-201

Phase 2

Indications: Complicated urinary tract infections, Complicated intra-abdominal infections, Nosocomial pneumonia

Partnerships

Rights to key assets acquired from Astellas Pharma Inc.acquired by Cubist Pharmaceuticals

Beyond the preview

Go deeper on Calixa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calixa Therapeutics.

Explore the full profile